FDA Accepts Gilead's Yeztugo sNDA for First Once-Weekly Oral HIV Prevention

Key Facts

1The U.S. FDA accepted Gilead's sNDA for Yeztugo (lenacapavir) as a potential once-weekly oral PrEP option for HIV prevention.

2The FDA has set a PDUFA action date of February 2, 2027, for the regulatory decision on the application.

In a move that strengthens Gilead's leadership in the antiviral sector, the U.S. FDA has accepted the company's application for Yeztugo as the first once-weekly oral PrEP option for HIV prevention. This regulatory milestone follows positive results from the PURPOSE 1 and PURPOSE 2 clinical trials, which aimed to provide long-acting alternatives for users. The FDA has established a PDUFA action date of February 2, 2027, for the final regulatory decision on the application.

This regulatory progress comes as competition in the HIV prevention (PrEP) market shifts toward long-acting formulations, with Gilead competing against peers like GSK, whose drug Apretivic has seen significant sales growth. Per market data, Gilead aims for Yeztugo (lenacapavir) to defend its market share, which exceeds 70% in the PrEP category, especially as patents for some of its legacy treatments approach expiration. Analysts view a potential approval as a critical driver for the company's long-term revenue growth.

Investors should monitor GILD stock levels, which closed at $125.59 (close June 12, 2026) after trading between a low of $124.29 and a high of $126.51. According to the economic calendar, while there are no immediate biotech-specific catalysts in the coming days, recent U.S. inflation data (4.2% YoY on June 10) continues to influence broader market sentiment for growth stocks. Focus will remain on any interim FDA updates leading up to the 2027 decision date.